Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS

Publication ,  Conference
Brown, D; Bacha, J; Wagner, L; Leggas, M; Kanekal, S; Lopez, L; Sankar, N
Published in: Neuro Oncology
2020

Duke Scholars

Published In

Neuro Oncology

EISSN

1523-5866

ISSN

1522-8517

Publication Date

2020

Volume

22

Start / End Page

60 / 60

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brown, D., Bacha, J., Wagner, L., Leggas, M., Kanekal, S., Lopez, L., & Sankar, N. (2020). A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS. In Neuro Oncology (Vol. 22, pp. 60–60).
Brown, Dennis, Jeffrey Bacha, Lars Wagner, Markos Leggas, Sarath Kanekal, Lorena Lopez, and Neil Sankar. “A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS.” In Neuro Oncology, 22:60–60, 2020.
Brown D, Bacha J, Wagner L, Leggas M, Kanekal S, Lopez L, et al. A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS. In: Neuro Oncology. 2020. p. 60–60.
Brown D, Bacha J, Wagner L, Leggas M, Kanekal S, Lopez L, Sankar N. A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS. Neuro Oncology. 2020. p. 60–60.
Journal cover image

Published In

Neuro Oncology

EISSN

1523-5866

ISSN

1522-8517

Publication Date

2020

Volume

22

Start / End Page

60 / 60

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences